© 2025 by Trienix Pharma. Powered and secured by Wix
18 November 2025
In Collaboration with Trienix Pharma, CQDM Invests for Development of an Innovative Lipid Analogues to Address Liver Inflammation
Trienix Pharma Inc. is partnering with Prof. André Marette, from the Faculty of Medicine and the Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval, as well as the CHU de Québec – Université Laval Research Center, to develop a new class of therapeutic lipids inspired by specialized pro-resolving mediators (SPMs), natural molecules that help resolve inflammation. These analogues activate the liver’s natural repair mechanisms, offering enhanced efficacy, fewer side effects, and an optimized pharmacological profile that marks a clear departure from current treatment approaches.
Through a synergy of expertise in medicinal chemistry, cell biology, and pharmacology, the project will lead to the creation of a library of therapeutic compounds for which Trienix Pharma Inc. will be able to obtain an exclusive license. The most promising analogues will undergo advanced preclinical validation, paving the way for clinical trials and the commercialization of new therapies.
This initiative could result in five to ten patent applications, strengthening the value and innovation of Quebec’s publicly funded research and its visibility in the health innovation sector. It also positions Trienix Pharma Inc. favorably to raise capital and establish strategic partnerships for clinical development.
13 November 2025
Appointment of Pierre Lemieux as Chief Executive Officer of Trienix Pharma
The Board of Directors of Trienix Pharma is pleased to announce the appointment of Pierre Lemieux, Ph.D., as Chief Executive Officer (CEO). This strategic decision reflects the company’s ambition to accelerate innovation in biotechnology, particularly in the development of next-generation lipid-based medicines targeting metabolic diseases, inflammatory conditions, and both acute and chronic pain.
With more than 30 years of experience in the biopharmaceutical sector, Dr. Lemieux has led translational research and clinical development programs, contributing to the advancement and value creation of innovative technology platforms. His expertise spans the entire biotechnology continuum: from molecular design to clinical validation, as well as public and private financing, the structuring of interdisciplinary teams, and the management of business and strategic partnerships.
Dr. Lemieux holds a Ph.D. in biochemistry from Université Laval and completed a postdoctoral fellowship at the University of Texas Health Science Center at San Antonio. He is recognized for his entrepreneurial leadership, with more than 50 scientific publications and 15 patents covering disruptive therapeutic approaches developed across four biopharmaceutical companies, notably in the field of specialized lipid mediators.
“I am honored to join Trienix at a pivotal moment in its evolution. Together, we will propel Trienix’s biotechnology platform by applying pharmaceutical development principles to transform scientific discoveries into tangible therapeutic solutions for patients,” said Dr. Lemieux.
Under his leadership, Trienix Pharma will focus on:
-
Accelerating the transition of preclinical programs toward clinical studies through an integrated biotechnology approach;
-
Strengthening business, industrial, and academic partnerships to foster the emergence of innovative synergies;
-
Establishing a sustainable culture of innovation centered on scientific excellence and high-quality outcomes.
26 October 2025
Prof. André Marette’s research group has just published a new article in The FASEB Journal highlighting the therapeutic potential of Protectin DX (PDX) analogs for the treatment of MASLD and diabetes.
Dr Marette's research group describe the preclinical evaluation of a novel synthetic analogue of the specialized pro-resolving mediator Protectin DX (“TP-48”), demonstrating in vivo efficacy in ameliorating hepatic steatosis and inflammation in animal models of metabolic dysfunction. TP‐48 (0.05 mg/kg) administered orally daily (as prodrug of TP-43) was found to fully prevent hepatic triglyceride accretion in diet‐induced obese hamsters. AN‐48 also prevented fasting hyperinsulinemia, insulin resistance, and reduced hepatic inflammation as compared to vehicle or PDX treatments. These results identify AN‐48 as a cost‐efficient and novel PDX analogue with high therapeutic potential against obesity‐linked T2D and MASLD. The study supports the translational potential of pro-resolving mediator-based therapies in metabolic liver disorders and aligns closely with Trienix Pharma’s strategic focus on developing next-generation small-molecule modulators of resolution biology.
6 August 2025
Trienix Pharma warmly welcome Pr Ru-Rong Ji as members of our Scientific Advisory Board
Pr Ji is the chief of pain research within Duke Anesthesiology, director of the Center for Translational Pain Medicine, and a professor of anesthesiology and neurobiology. As director of the Sensory Plasticity and Pain Research Laboratory at Duke, his research focuses on molecular and cellular mechanisms of chronic pain, such as inflammatory pain, neuropathic pain, and cancer pain. He is internationally-recognized for his contributions.
1st August 2025
Trienix Pharma announces the launch of its brand-new website!
4 December 2024
Trienix Pharma is proud to announce the appointment of
Dr. Charles Serhan to its Scientific Advisory Board
Dr. Serhan is a world-renowned pioneer in the field of specialized pro-resolving mediators (SPMs), whose seminal discoveries have redefined the biology of inflammation resolution and opened new therapeutic frontiers. He is the Simon Gelman Professor of Anaesthesia at Harvard Medical School and Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital. Dr. Serhan is also President and CEO of the International Eicosanoid Research Foundation, and has authored over 600 peer-reviewed publications, earning recognition among the world’s most cited scientists. His unparalleled expertise and leadership in translating SPM biology into innovative clinical applications will be instrumental in guiding Trienix Pharma’s R&D strategy, particularly in advancing our proprietary Protectin DX (PDX) analog platform toward transformative therapies in pain control, metabolic liver disease, and inflammation-driven disorders.
28 November 2024
Trienix Pharma signs an exclusive licence with University Laval for the use of synthetic analogs of protectin DX and for other synthetic SPMs analogs
